ArticleJournal of endocrinological investigation2025
The overweight and obesity landscape in italy: data from the Italy cohort of the multi-country IMPACT-O study.
Article in Journal of endocrinological investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- "One-stop-shop" medical imaging for osteoporosis and obese patients: a narrative review.Journal of endocrinological investigation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThe IMPACT-O study was a multi-country, retrospective cohort study that utilized healthcare databases to describe the landscape/impact of obesity. Here, we describe the characteristics and management of adults with a first record of overweight/obesity or obesity in Italy between 2018 and 2022.
methodsThe IQVIA longitudinal patient database in Italy was used to identify individuals with a first record of overweight/obesity, as determined by diagnosis codes and/or body mass index (BMI) measurements (overweight/obesity cohort: BMI ≥ 25 kg/m
resultsThe overweight/obesity cohort included 38,144 individuals, and the obesity cohort 16,489 individuals. Most individuals with overweight/obesity (72.7%) and obesity (77.1%) presented with ≥ 1 ORCs. The most frequent ORCs among people with obesity were hypertension (48.0%), dyslipidemia (26.2%), osteoarthritis (23.9%), and type 2 diabetes (14.0%). The proportion of individuals receiving pharmacological therapies with an effect on weight was ≤ 1%; there were no records of lifestyle interventions or bariatric surgery.
conclusionsThis analysis suggests a high rate of ORCs in people with overweight or obesity at first available record, and limited use of pharmacological treatment with an effect on weight. This highlights the need for prompt recognition and formal diagnosis of overweight and obesity in healthcare settings, accompanied by early and intensive intervention. Patient management could be improved with a systematic and centralized recording of all interventions in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.